Table 2.
Demographics and baseline characteristics for the all-tofacitinib comparison cohort and the observational comparison cohort
| Characteristics | All-tofacitinib comparison cohort (n = 783) | Observational comparison cohort (n = 5799) |
|---|---|---|
| Age (years) | 48.7 ± 12.0 | 48.9 ± 11.5 |
| Female | 428 (54.7) | 3127 (53.9) |
| Race | ||
| White | 739 (94.4) | NA |
| Black | 3 (0.4) | NA |
| Asian | 23 (2.9) | NA |
| Other | 18 (2.3) | NA |
| Geographical regiona | ||
| USA/Canada | 158 (20.2) | 5799 (100.0) |
| Eastern Europe/Russia | 369 (47.1) | 0 (0.0) |
| Western Europe/Australia | 173 (22.1) | 0 (0.0) |
| Asia | 15 (1.9) | 0 (0.0) |
| Latin America | 68 (8.7) | 0 (0.0) |
| PsA duration (years) | 7.7 ± 7.2 | NA |
| Diabetes | 107 (13.7) | 706 (12.2) |
| Prior TNFi experience | 377 (48.1) | 2125 (36.6) |
| Corticosteroid useb | 170 (21.7) | 856 (11.9) |
| Concomitant MTX | 609 (77.8) | 2202 (38.0) |
Data are presented as mean ± standard deviation or N (%) unless otherwise indicated
MTX methotrexate, NA not available, PsA psoriatic arthritis, TNFi tumor necrosis factor inhibitor
aEastern Europe includes Bulgaria, Czech Republic, Hungary, and Poland. Western Europe includes Belgium, France, Germany, Spain, and the UK. Asia includes Taiwan. Latin America includes Brazil and Mexico
bOral systemic corticosteroid use at baseline (maximum dose 10 mg/day prednisone equivalent)